Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Net Margin (2020 - 2025)

Foghorn Therapeutics has reported Net Margin over the past 6 years, most recently at 239.71% for Q4 2025.

  • Quarterly results put Net Margin at 239.71% for Q4 2025, up 44317.0% from a year ago — trailing twelve months through Dec 2025 was 251.2% (up 13204.0% YoY), and the annual figure for FY2025 was 251.2%, up 13204.0%.
  • Net Margin for Q4 2025 was 239.71% at Foghorn Therapeutics, down from 202.0% in the prior quarter.
  • Over the last five years, Net Margin for FHTX hit a ceiling of 82.07% in Q3 2023 and a floor of 65268.29% in Q3 2021.
  • Median Net Margin over the past 5 years was 511.01% (2023), compared with a mean of 4640.0%.
  • Biggest five-year swings in Net Margin: plummeted -5482639bps in 2021 and later skyrocketed 6487985bps in 2022.
  • Foghorn Therapeutics' Net Margin stood at 3998.32% in 2021, then surged by 83bps to 690.39% in 2022, then surged by 39bps to 417.85% in 2023, then plummeted by -63bps to 682.88% in 2024, then soared by 65bps to 239.71% in 2025.
  • The last three reported values for Net Margin were 239.71% (Q4 2025), 202.0% (Q3 2025), and 248.62% (Q2 2025) per Business Quant data.